Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) Short Interest Update

by · The Markets Daily

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 225,427 shares, a decrease of 45.5% from the May 14th total of 413,714 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 760,388 shares, the short-interest ratio is currently 0.3 days.

Coloplast A/S Stock Up 0.3%

OTCMKTS CLPBY traded up $0.02 during trading on Tuesday, hitting $5.94. 132,353 shares of the company traded hands, compared to its average volume of 557,186. The company has a market capitalization of $13.39 billion, a P/E ratio of 42.43, a PEG ratio of 1.90 and a beta of 0.18. The business has a fifty day simple moving average of $6.36 and a 200 day simple moving average of $7.46. Coloplast A/S has a 12 month low of $5.83 and a 12 month high of $10.03. The company has a current ratio of 1.30, a quick ratio of 0.81 and a debt-to-equity ratio of 1.50.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a return on equity of 31.96% and a net margin of 7.46%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. As a group, sell-side analysts predict that Coloplast A/S will post 0.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. The Goldman Sachs Group downgraded Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Coloplast A/S presently has an average rating of “Hold”.

Check Out Our Latest Stock Report on Coloplast A/S

About Coloplast A/S

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

Read More